by GlobeNewsWire | Jan 11, 2016 | Globe Newswire, GNW Alerts
ST. LOUIS, Jan. 11, 2016 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it has initiated its first prospective, multi-center, randomized clinical study...
by GlobeNewsWire | Nov 3, 2015 | Globe Newswire
-Total Quarterly Revenue Increased 5% Year over Year on Improved System and Recurring Revenues- -Total Revenue for First Nine Months Increased 13% Year over Year to $28.5 Million- -System Revenue for First Nine Months Increased 76% Year over Year to $8.2...
by GlobeNewsWire | Oct 27, 2015 | Globe Newswire
ST. LOUIS, Oct. 27, 2015 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 third quarter ended September...
by GlobeNewsWire | Oct 8, 2015 | Globe Newswire
ST. LOUIS, Oct. 08, 2015 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (“Stereotaxis”) (NASDAQ:STXS) a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of its previously announced offering of subscription...
by GlobeNewsWire | Sep 21, 2015 | Globe Newswire
ST. LOUIS, Sept. 21, 2015 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that J. David Burkhardt, M.D. of the Texas Cardiac Arrhythmia Institute (TCAI) at...